Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR

References

• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 1995;19(3):183–232.
   PubMed Web of Science ®Google Scholar
• Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010;1804(3):559–566.
   PubMed Web of Science ®Google Scholar
• Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL. Structure and dynamics of the EGF receptor as revealed by experiments and simulations and its relevance to non-small cell lung cancer. Cells. 2019;8(4):316.
   PubMed Web of Science ®Google Scholar
• Sutto L, Gervasio FL. Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci U S A. 2013;110(26):10616–10621.
   PubMed Web of Science ®Google Scholar
• Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins. 2006;65(2):331–346.
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Zarogoulidis P, Darwiche K, Boutsikou E, Machairiotis N, Tsakiridis K, Katsikogiannis N, Kougioumtzi I, Karapantzos I, Huang H, et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis. 2013;5:S389–S396.
   PubMed Web of Science ®Google Scholar
• Alexander M, Kim SY, Cheng H. Update 2020: management of non-small cell lung cancer. Lung. 2020;198(6):897–907.
   PubMed Web of Science ®Google Scholar
• Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29(suppl_1):i10–i19.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors—impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7(9):493–507.
   PubMed Web of Science ®Google Scholar
• Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, Xu C, Rhee K, Chen T, Zhang H, Palakurthi S, et al. Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Tripathi SK, Biswal BK. Allosteric mutant-selective fourth-generation EGFR inhibitors as an efficient combination therapeutic in the treatment of non-small cell lung carcinoma. Drug Discov Today. 2021;26(6):1466–1472.
   PubMed Web of Science ®Google Scholar
• Caporuscio F, Tinivella A, Restelli V, Semrau MS, Pinzi L, Storici P, Broggini M, Rastelli G. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking. Future Med Chem. 2018;10(13):1545–1553.
   PubMed Web of Science ®Google Scholar
• Rastelli G, Anighoro A, Chripkova M, Carrassa L, Broggini M. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2. Cell Cycle. 2014;13(14):2296–2305.
   PubMed Web of Science ®Google Scholar
• Christodoulou MS, Caporuscio F, Restelli V, Carlino L, Cannazza G, Costanzi E, Citti C, Lo Presti L, Pisani P, Battistutta R, et al. Probing an allosteric pocket of CDK2 with small molecules. ChemMedChem. 2017;12(1):33–41.
   PubMed Web of Science ®Google Scholar
• Carlino L, Christodoulou MS, Restelli V, Caporuscio F, Foschi F, Semrau MS, Costanzi E, Tinivella A, Pinzi L, Lo Presti L, et al. Structure-activity relationships of hexahydrocyclopenta[c]quinoline derivatives as allosteric inhibitors of CDK2 and EGFR. ChemMedChem. 2018;13(24):2627–2634.
   PubMed Web of Science ®Google Scholar
• Bonandi E, Perdicchia D, Colombo E, Foschi F, Marzullo P, Passarella D. C3 Aza-alkylation of indoles. Org Biomol Chem. 2020;18(32):6211–6235.
   PubMed Web of Science ®Google Scholar
• Christodoulou MS, Beccalli EM, Foschi F, Giofrè S. Pd-catalyzed domino reactions involving alkenes to access substituted indole derivatives. Synthesis. 2020;52(19):2731–2760.
   Web of Science ®Google Scholar
• Papis M, Loro C, Penso M, Broggini G, Foschi F. Synthesis of morpholino nucleosides starting from enantiopure glycidol. Org Chem Front. 2022;9(11):2949–2954.
   Web of Science ®Google Scholar
• Quici S, Casoni A, Foschi F, Armelao L, Bottaro G, Seraglia R, Bolzati C, Salvarese N, Carpanese D, Rosato A. Folic acid-conjugated europium complexes as luminescent probes for selective targeting of cancer cells. J Med Chem. 2015;58(4):2003–2014.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shaw DE, Shelley M, Perry JK, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739–1749.
   PubMed Web of Science ®Google Scholar
• Tinivella A, Rastelli G. Investigating the selectivity of allosteric inhibitors for mutant T790M EGFR over wild type using molecular dynamics and binding free energy calculations. ACS Omega. 2018; 3(12):16556–16562.
   Web of Science ®Google Scholar
• Zhao Z, Xie L, Bourne PE. Structural insights into characterizing binding sites in epidermal growth factor receptor kinase mutants. J Chem Inf Model. 2019;59(1):453–462.
   PubMed Web of Science ®Google Scholar
• Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49(2):534–553.
   PubMed Web of Science ®Google Scholar
• Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006;67(1):83–84.
   PubMed Web of Science ®Google Scholar